Skip to content

OS Therapies OSTX Earnings yield

Earnings yield at other companies

Immunome logo
ImmunomeIMNM
-9.1%-3.9pp
CTO
Citius Oncology, Inc.CTOR
-77.7%+7,484pp
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-24.9%-110pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-13.6%-5.7pp
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-10.8%-2.6pp
WHW
Whitehawk Therapeutics, Inc. Common StockWHWK
-71.1%

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K
Free cash flow-$3.7M

Valuation

See full
Market cap$84.62M+65.5%
Enterprise value$103.7M

Returns & leverage

See full
Return on equity470%
Debt / equity-1.8×
Current ratio0.1×-1.1×

Where this comes from

Calculated from OS Therapies’s reported figures.

Based on trailing twelve months.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's earnings yield?
OS Therapies (OSTX) reported earnings yield of -71% in Q1 2026.
How has OS Therapies's earnings yield changed year-over-year?
OS Therapies's earnings yield decreased by 110.7% year-over-year, from -33.7% to -71%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.